Aquestive Therapeutics (NASDAQ:AQST) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research note issued to investors on Tuesday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $17.00 target price on the stock. Cantor Fitzgerald also issued estimates for Aquestive Therapeutics’ FY2024 earnings at ($0.45) EPS.

A number of other brokerages have also recently commented on AQST. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Wednesday, November 6th. Finally, Leerink Partners lifted their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $11.00.

Aquestive Therapeutics Stock Up 5.2 %

Shares of NASDAQ AQST opened at $3.64 on Tuesday. The firm has a market cap of $331.89 million, a P/E ratio of -8.09 and a beta of 2.62. Aquestive Therapeutics has a twelve month low of $1.84 and a twelve month high of $6.23. The company has a 50 day moving average of $4.74 and a 200 day moving average of $4.06.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million for the quarter, compared to the consensus estimate of $12.69 million. During the same quarter in the prior year, the company earned ($0.03) EPS. As a group, equities analysts expect that Aquestive Therapeutics will post -0.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Verition Fund Management LLC bought a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at approximately $995,000. Blue Owl Capital Holdings LP raised its stake in Aquestive Therapeutics by 30.3% during the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock valued at $2,964,000 after purchasing an additional 265,000 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Aquestive Therapeutics during the second quarter valued at $594,000. Chartwell Investment Partners LLC bought a new stake in shares of Aquestive Therapeutics in the 3rd quarter worth about $535,000. Finally, GSA Capital Partners LLP raised its position in shares of Aquestive Therapeutics by 525.5% during the 3rd quarter. GSA Capital Partners LLP now owns 137,151 shares of the company’s stock valued at $683,000 after buying an additional 115,223 shares in the last quarter. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.